What is the market's earnings forecast for Humana next quarter?

What factors drove the changes in Humana's revenue and profit?

Did Humana beat or miss consensus estimates last quarter?

What guidance did Humana's management provide for the next earnings period?

What is the revenue and EPS growth rate for Humana year over year?

What is Humana's latest dividend and current dividend yield?

What does Humana do and what are its main business segments?

What were the key takeaways from Humana’s earnings call?

- **MA Growth Strategy**: Prioritizes retention over new sales, with channel mix focused on high-value segments. Stars recovery progress visible in '28, though '27 results disappointing.
- **Financial Discipline**: $17 EPS target reaffirmed despite $150M investments. Capital allocation balanced between M&A and debt management.
- **Key Metrics**: Reduced plan-to-plan sales (down YoY), 600K+ gaps closed in '28, and DCP timing-driven changes highlight operational focus.
- **Long-Term Vision**: Shift to LTV/Stars-driven margin, with 2026 MA margin doubling 2025 levels if Stars thresholds align.

**【CEO Summary Section】**
- **Medicare Advantage (MA) Growth Strategy**: Emphasized focus on retention over new sales, with new sales at the high end of expectations. Retention rates are a key metric, with reduced plan-to-plan sales (down year-over-year), indicating better member stability. However, specific growth targets are withheld due to operational capacity concerns.
- **Channel Mix Optimization**: Greater volume in high-performing partner and digital channels, which correlate with higher lifetime value. Avoiding outsized sales in low-margin plans to maintain operational efficiency.
- **Stars Program Recovery**: Bonus Year '27 results were disappointing but consistent with expectations. Bonus Year '28 shows early operational progress, with 600,000 more gaps closed year-over-year, though final results depend on thresholds.
- **Long-Term Value (LTV) Framework**: Shift to lifetime value and NPV as primary metrics, balancing short-term margin with long-term sustainability. Avoiding the cycle of low-margin, high-growth products.

**【CFO Financial Commentary】**
- **Third-Quarter Performance**: Solid execution with medical cost trends in line with expectations. Reaffirmed full-year adjusted EPS outlook of $17, despite incremental investments ($150 million) in Stars and network management.
- **Capital Allocation**: Proceeding with non-core asset sales (e.g., Enclara Pharmacia) and M&A (e.g., Villages Health). Debt-to-cap ratio at 40.3%, targeting ~40% long-term. Share buybacks offset dilution from stock-based compensation.
- **Balance Sheet Management**: DCP metric reflects timing variations, not reserve levels. IBNR consistency supports claims reserve strength, despite individual MA membership decline.

**【Q&A Highlights】**
- **Membership Growth Dynamics**: New sales at the high end of expectations, but operational capacity limits transparency on exact numbers. Focus on channel mix (e.g., digital, high-performing partners) to mitigate risk.
- **Stars Mitigation Efforts**: Proactive measures with providers, including contract changes and Stars mitigation programs. Progress in 2026 will depend on provider partnerships and Stars thresholds.
- **2026 Outlook**: MA margin expected to double 2025 levels, driven by product design and channel mix. However, final results hinge on Stars performance and operational execution.
- **Market Trends**: CMS forecasts suggest mid-single-digit MA growth, consistent with historical patterns. Humana remains below or at parity with competitors in key geographies, limiting fee-for-service attrition risk.

Humana Inc. (HUM) Q3 2025 Earnings Call Transcript

External Customers

Investment Income

Centerwell

HUM

HUM fundamentals

You can ask Aime